COVID-19 infection impact on cardiovascular and thrombotic events during acute phase and medium-term of the disease. (14th October 2021)

• Record Type: Journal Article
• Authors: Varela Lopez, A; Diaz Argueso, L; Broco Fernandez, C; Cacho Antonio, C E; Antunez Muinos, P J; Otero Garcia, O; Jimenez Ramons, V; Gonzalez Ferreiro, T; Perez-Poza, M; Bastos Fernandez, M; Garcia Campos, A; Varela Roman, A; Lopez Pais, J; Lopez Otero, D; Gonzalez Juanatey, J R
• Is Part Of: European heart journal. Volume 42(2021)Supplement 1
• Publication Date: 2021-10-14
• Subjects: Cardiovascular Disease in Primary Care; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/ehab724.2726
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Background: Coronavirus disease (COVID-19) was labelled a global pandemic in April 2020 by the World Health Organisation. By December of the same year the disease caused by SARS-COV-2, known as COVID-19 (Coronavirus disease 2019), had spread over 200 countries, infecting more than 70 million people, causing more that 1.5 million of deaths. Recent studies suggest SARS-CoV-2 infection may be related to cardiovascular and thrombotic events although the strength of association remains unclear. Aims: Evaluate the emergence of cardiovascular and thrombotic events (such as major acute cardiovascular events, ictus and other thrombosis) in the acute moment and in medium-term follow-up in COVID-19 patients. Methods: Single-Center, retrospective, observational study of cohorts based on all the inhabitants of the health area. Survival analysis of main outcomes (mortality, heart failure [HF], and major acute cardiovascular events – MACE - [a composite of cardiovascular mortality, myocardial infarction and stroke]) were adjusted by multivariate logistic regression. Results: Of the total population studied, 447, 979 inhabitants, 1, 030 (0.23%) were diagnosed with COVID-19 infection, of which 14, 8% were smokers, 31, 2% had high blood pressure (HTA), 12, 8% had diabetes, 29, 2% had dyslipidaemia, 2, 7% had peripheral artery disease, 4, 7% had ischemic heart disease, 3, 3% had had a previous transient ischemic attack, 10% were in anti-aggregation treatment and 5, 8% were in anticoagulation treatment at the time of diagnosis. Concerning the analytics middle values, the group treated with ACEI/ARAB had higher troponins and ferritin than the group without ACEI/ARAB treatment, whereas higher reactive C protein and D-dimer were found in this last group. The main results showed that COVID-19 infection had no effect regarding to cardiovascular and thrombotic disease on mortality (OR: 1.64, 95% CI 0.98 2.76, p=0.062), heart failure (OR: 0.98, 95% CI 0.53 1.79, p=0.942), thrombotic events (OR: 1.02, 95% CI 0.22 4.83, p=0.98) and major acute cardiovascular events (OR: 0.88, 95% CI 0.48 1.60, p=0.665). Conclusions: In conclusion, COVID-19 infection had no effect on the emergence of cardiovascular or thrombotic events taking into account the 6-month prognosis, defined as mortality, heart failure, or major acute cardiovascular events. FUNDunding Acknowledgement: Type of funding sources: None.